Nifty
Sensex
:
:
13258.55
45079.55
124.65 (0.95%)
446.90 (1.00%)

Pharmaceuticals & Drugs - API

Rating :
81/99

BSE: 532482 | NSE: GRANULES

422.05
04-Dec-2020
  • Open
  • High
  • Low
  • Previous Close
  •  426.25
  •  429.90
  •  420.00
  •  419.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1162705
  •  4945.31
  •  437.95
  •  114.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,445.68
  • 24.21
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 11,053.84
  • 0.24%
  • 5.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 42.04%
  • 4.20%
  • 24.15%
  • FII
  • DII
  • Others
  • 26.31%
  • 0.14%
  • 3.16%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.52
  • 13.87
  • 15.54

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.03
  • 13.75
  • 13.54

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 30.95
  • 19.93
  • 38.52

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.20
  • 17.77
  • 14.97

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.89
  • 2.96
  • 2.34

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.63
  • 10.64
  • 10.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
858.12
699.53
22.67%
735.60
595.27
23.57%
599.88
613.32
-2.19%
703.96
631.78
11.42%
Expenses
601.71
555.93
8.23%
552.01
476.65
15.81%
499.94
515.71
-3.06%
540.81
518.48
4.31%
EBITDA
256.41
143.60
78.56%
183.59
118.62
54.77%
99.95
97.61
2.40%
163.15
113.30
44.00%
EBIDTM
29.88%
20.53%
24.96%
19.93%
14.01%
15.91%
23.18%
17.93%
Other Income
3.22
8.67
-62.86%
5.63
1.86
202.69%
22.52
1.88
1,097.87%
3.51
5.88
-40.31%
Interest
6.27
6.85
-8.47%
5.95
6.87
-13.39%
6.57
6.85
-4.09%
6.73
7.47
-9.91%
Depreciation
36.06
30.32
18.93%
34.08
28.67
18.87%
38.97
27.42
42.12%
38.99
27.01
44.35%
PBT
217.30
115.10
88.79%
149.19
84.94
75.64%
136.70
65.22
109.60%
88.90
84.69
4.97%
Tax
53.67
19.31
177.94%
37.74
27.19
38.80%
44.36
20.18
119.82%
24.87
26.46
-6.01%
PAT
163.63
95.79
70.82%
111.45
57.75
92.99%
92.34
45.04
105.02%
64.03
58.23
9.96%
PATM
19.07%
13.69%
15.15%
9.70%
7.11%
7.34%
9.10%
9.22%
EPS
6.61
3.87
70.80%
4.50
2.33
93.13%
3.73
1.82
104.95%
2.59
2.35
10.21%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
2,897.56
2,598.65
2,279.20
1,684.62
1,410.57
1,357.18
1,292.92
1,095.86
764.37
653.97
475.18
Net Sales Growth
14.08%
14.02%
35.29%
19.43%
3.93%
4.97%
17.98%
43.37%
16.88%
37.63%
 
Cost Of Goods Sold
5,649.86
1,280.93
1,255.56
896.32
679.63
725.03
746.95
645.25
466.92
414.36
295.55
Gross Profit
-2,752.30
1,317.72
1,023.64
788.30
730.93
632.15
545.97
450.61
297.45
239.60
179.63
GP Margin
-94.99%
50.71%
44.91%
46.79%
51.82%
46.58%
42.23%
41.12%
38.91%
36.64%
37.80%
Total Expenditure
2,194.47
2,073.33
1,895.16
1,406.20
1,111.73
1,081.29
1,084.31
937.57
679.35
574.68
418.92
Power & Fuel Cost
-
59.74
57.67
48.22
38.67
34.97
45.73
36.70
37.71
26.28
23.07
% Of Sales
-
2.30%
2.53%
2.86%
2.74%
2.58%
3.54%
3.35%
4.93%
4.02%
4.86%
Employee Cost
-
259.04
209.82
165.21
140.19
117.57
106.96
85.84
59.71
45.46
33.38
% Of Sales
-
9.97%
9.21%
9.81%
9.94%
8.66%
8.27%
7.83%
7.81%
6.95%
7.02%
Manufacturing Exp.
-
177.94
157.62
120.84
88.60
66.97
50.89
38.68
24.34
18.90
14.71
% Of Sales
-
6.85%
6.92%
7.17%
6.28%
4.93%
3.94%
3.53%
3.18%
2.89%
3.10%
General & Admin Exp.
-
125.63
99.96
83.05
67.65
60.38
59.84
44.42
26.96
21.31
16.52
% Of Sales
-
4.83%
4.39%
4.93%
4.80%
4.45%
4.63%
4.05%
3.53%
3.26%
3.48%
Selling & Distn. Exp.
-
112.17
91.84
83.08
81.37
67.75
71.70
85.04
61.70
47.62
32.32
% Of Sales
-
4.32%
4.03%
4.93%
5.77%
4.99%
5.55%
7.76%
8.07%
7.28%
6.80%
Miscellaneous Exp.
-
57.88
22.69
9.49
15.61
8.62
2.24
1.64
2.01
0.74
32.32
% Of Sales
-
2.23%
1.00%
0.56%
1.11%
0.64%
0.17%
0.15%
0.26%
0.11%
0.71%
EBITDA
703.10
525.32
384.04
278.42
298.84
275.89
208.61
158.29
85.02
79.29
56.26
EBITDA Margin
24.27%
20.22%
16.85%
16.53%
21.19%
20.33%
16.13%
14.44%
11.12%
12.12%
11.84%
Other Income
34.88
36.56
26.68
10.84
9.93
5.62
4.34
4.31
2.06
1.38
0.80
Interest
25.52
27.02
28.46
33.06
32.26
37.07
32.35
20.43
17.67
16.99
11.99
Depreciation
148.10
136.95
105.48
76.20
71.51
58.40
52.65
29.81
23.08
20.70
18.31
PBT
592.09
397.90
276.78
180.00
204.99
186.03
127.96
112.36
46.32
42.98
26.76
Tax
160.64
115.73
89.11
63.40
65.20
61.15
37.05
37.13
13.76
13.02
5.86
Tax Rate
27.13%
27.19%
32.20%
35.22%
31.81%
32.87%
28.95%
33.05%
29.71%
30.29%
21.90%
PAT
431.45
309.91
187.67
116.60
139.79
124.89
90.91
75.23
32.57
29.95
20.90
PAT before Minority Interest
431.45
309.91
187.67
116.60
139.79
124.89
90.91
75.23
32.57
29.95
20.90
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
14.89%
11.93%
8.23%
6.92%
9.91%
9.20%
7.03%
6.86%
4.26%
4.58%
4.40%
PAT Growth
68.00%
65.14%
60.95%
-16.59%
11.93%
37.38%
20.84%
130.98%
8.75%
43.30%
 
EPS
17.43
12.52
7.58
4.71
5.65
5.04
3.67
3.04
1.32
1.21
0.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
1,843.72
1,529.47
1,304.18
903.60
661.60
431.16
355.96
274.85
245.09
219.78
Share Capital
25.42
25.42
25.38
22.87
21.67
20.43
20.28
20.13
20.06
20.06
Total Reserves
1,800.02
1,493.09
1,273.38
878.28
611.13
410.74
335.43
254.41
225.03
199.72
Non-Current Liabilities
485.98
552.63
488.19
187.99
246.62
356.52
343.51
202.00
112.60
58.88
Secured Loans
414.83
478.78
433.13
123.90
183.66
302.59
295.86
174.85
87.30
37.08
Unsecured Loans
6.69
0.00
0.00
0.34
0.55
0.62
13.38
0.65
0.75
0.75
Long Term Provisions
21.50
12.58
7.70
7.25
5.58
4.03
3.97
2.04
1.53
1.19
Current Liabilities
966.54
896.48
877.91
787.13
654.75
415.03
292.54
205.78
213.63
157.11
Trade Payables
430.02
323.48
274.35
215.98
181.10
187.63
135.54
91.84
75.52
51.81
Other Current Liabilities
153.16
113.60
69.84
93.43
79.21
88.98
47.78
23.77
31.39
18.65
Short Term Borrowings
371.69
454.21
525.10
473.83
392.85
124.97
100.91
85.46
102.06
83.15
Short Term Provisions
11.66
5.20
8.62
3.90
1.58
13.45
8.30
4.71
4.66
3.50
Total Liabilities
3,296.24
2,978.58
2,670.28
1,878.72
1,562.97
1,202.71
992.01
682.63
571.32
435.77
Net Block
1,203.97
944.25
776.73
644.34
559.94
616.55
482.47
263.46
250.42
238.62
Gross Block
1,875.23
1,472.94
1,199.63
983.66
822.98
843.76
653.90
387.41
354.50
322.61
Accumulated Depreciation
671.26
528.69
422.90
339.32
263.05
227.21
171.43
123.95
104.07
83.99
Non Current Assets
1,594.41
1,696.34
1,483.71
1,050.55
744.97
699.69
611.55
388.87
310.52
256.75
Capital Work in Progress
294.20
495.95
514.52
267.43
76.56
62.03
124.56
108.80
29.30
6.85
Non Current Investment
19.34
210.42
156.56
108.23
70.11
0.19
0.19
0.19
0.19
0.30
Long Term Loans & Adv.
76.89
45.72
35.91
30.56
38.37
20.76
4.33
16.42
30.50
10.71
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.15
0.00
0.00
0.12
0.27
Current Assets
1,701.84
1,282.24
1,186.57
828.16
818.00
500.36
376.92
288.88
260.26
179.02
Current Investments
109.85
0.00
0.00
0.00
0.00
0.00
0.00
9.46
0.00
0.00
Inventories
438.43
384.21
279.95
269.18
253.72
224.52
174.16
136.48
109.91
75.13
Sundry Debtors
735.18
673.54
628.25
417.70
375.35
136.91
110.91
71.02
95.01
71.61
Cash & Bank
283.94
89.04
115.64
49.80
130.29
65.31
41.75
41.71
31.98
11.99
Other Current Assets
134.43
36.99
48.64
39.83
58.65
73.63
50.10
30.21
23.36
20.29
Short Term Loans & Adv.
91.83
98.46
114.09
51.66
48.68
2.05
28.76
16.93
13.18
12.28
Net Current Assets
735.30
385.76
308.65
41.03
163.25
85.33
84.38
83.09
46.63
21.91
Total Assets
3,296.25
2,978.58
2,670.28
1,878.71
1,562.97
1,202.72
992.01
682.64
571.31
435.77

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
476.19
262.24
-0.65
188.24
151.43
150.28
107.95
91.18
25.60
48.56
PBT
425.64
276.78
180.00
204.99
186.03
127.96
112.36
46.32
42.98
26.76
Adjustment
156.88
149.85
107.45
95.14
92.63
85.37
50.39
41.46
37.74
33.11
Changes in Working Capital
12.75
-75.94
-230.03
-52.37
-79.70
-31.34
-31.03
14.60
-43.61
-5.70
Cash after chg. in Working capital
595.27
350.69
57.42
247.77
198.97
182.00
131.73
102.39
37.11
54.16
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-119.08
-88.45
-58.07
-59.53
-47.54
-31.72
-23.78
-11.20
-11.51
-5.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-160.63
-269.82
-462.31
-326.09
-161.65
-145.55
-254.63
-127.79
-54.47
-25.09
Net Fixed Assets
-124.57
-176.36
-282.01
-249.86
-75.62
-231.53
-64.60
-89.18
-54.67
-23.22
Net Investments
-48.78
-431.34
-0.01
13.84
-16.48
72.98
-94.69
-17.96
-10.20
0.00
Others
12.72
337.88
-180.29
-90.07
-69.55
13.00
-95.34
-20.65
10.40
-1.87
Cash from Financing Activity
-212.85
-17.43
528.62
55.87
85.67
18.83
146.72
46.33
48.86
-24.96
Net Cash Inflow / Outflow
102.70
-25.01
65.66
-81.98
75.44
23.56
0.04
9.72
19.99
-1.49
Opening Cash & Equivalents
83.02
108.03
42.37
124.35
54.85
41.75
41.71
31.98
11.99
13.47
Closing Cash & Equivalent
185.93
83.02
108.03
42.37
130.29
65.31
41.75
41.71
31.98
11.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
71.80
59.73
51.17
39.40
29.20
20.98
17.36
13.40
12.19
10.96
ROA
9.88%
6.64%
5.13%
8.12%
9.03%
8.31%
8.98%
5.19%
5.95%
4.91%
ROE
18.54%
13.32%
10.60%
18.23%
23.53%
23.29%
24.20%
12.67%
12.90%
9.98%
ROCE
17.22%
12.71%
11.09%
16.57%
20.16%
18.75%
19.90%
12.95%
14.89%
11.00%
Fixed Asset Turnover
1.75
1.78
1.55
1.59
1.66
1.77
2.14
2.11
1.96
1.54
Receivable days
87.91
100.03
112.83
100.84
67.60
33.47
29.73
38.66
45.82
52.00
Inventory Days
51.34
51.03
59.23
66.49
63.11
54.79
50.77
57.37
50.89
54.38
Payable days
64.46
54.96
62.37
64.87
59.99
53.57
43.67
44.19
40.05
38.81
Cash Conversion Cycle
74.78
96.10
109.70
102.46
70.72
34.69
36.83
51.84
56.66
67.57
Total Debt/Equity
0.49
0.65
0.75
0.73
1.01
1.14
1.25
1.00
0.83
0.63
Interest Cover
16.75
10.72
6.44
7.36
6.02
4.96
6.50
3.62
3.53
3.23

News Update:


  • Granules India’s arm gets USFDA nod for generic Penicillamine capsules
    4th Dec 2020, 09:29 AM

    The product would be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly

    Read More
  • Granules India gets nod to set up subsidiary in Hyderabad
    9th Nov 2020, 14:21 PM

    The Board of Directors at their meeting has approved to incorporate a wholly-owned subsidiary of the company in Hyderabad, India

    Read More
  • Granules India gets marketing approval from US FDA for Potassium Chloride Extended Release Tablets
    22nd Oct 2020, 10:46 AM

    The company has received approval from the US Food & Drug Administration

    Read More
  • Granules India reports 71% rise in Q2 consolidated net profit
    20th Oct 2020, 17:12 PM

    Total consolidated income of the company increased by 21.62% at Rs 861.34 crore for Q2FY21

    Read More
  • Granules India gets USFDA’s nod for Naproxen Sodium, Diphenhydramine Hydrochloride Tablets
    25th Sep 2020, 11:42 AM

    The company now has a total of 31 ANDA approvals from US FDA

    Read More
  • Granules India’s arm receives USFDA’s approval for Dexmethylphenidate HCl ER Capsules
    11th Sep 2020, 09:51 AM

    Granules’ capsule product is bioequivalent to the reference listed drug, Focalin XR

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.